The Memo: AI-Driven Tensor Surgical Redefines Orthopedic Soft Tissue Repair with Anchorless Innovation

Under the direction of President and CEO Justin Anderson, Tensor Surgical is challenging the status quo in sports medicine. Sixteen years ago, Anderson commercialized the first mover in the space and pioneered the adoption of minimally invasive “anchorless” arthroscopic transosseous rotator cuff repair. The company is the world’s leader in anchorless soft tissue repair with its truly novel TransOs Tunneler transosseous soft tissue repair system that eliminates the need for traditional suture anchors. By reducing implant costs while improving patient outcomes, Tensor Surgical is delivering a true value-based care solution—one that benefits patients, physicians, and healthcare systems alike.

With over 10,000 successful procedures performed, national contracts in place, and growing demand from major healthcare systems, Tensor Surgical is positioned to disrupt the orthopedic soft tissue repair market—and specifically rotator cuff repair—on a global scale, with its AI-driven approach to drive efficiency and profitability at scale.

Origin Story

Few people understand the evolution of arthroscopic surgery like Justin Anderson. With a career spanning nearly three decades, Anderson has been instrumental in creating entirely new surgical markets, from pioneering temperature-controlled radiofrequency technology for arthroscopy to developing the first knotless tensionable suture anchor for rotator cuff repair from shape memory nitinol to flying all around the world creating a market for the future of value-based rotator cuff and soft tissue repair…“anchorless” solutions, he commercialized that obviate the need for suture anchors, the single highest cost driver in rotator cuff repair globally. With six exits and two IPOs to his credit, Anderson’s deep domain experience is noteworthy.

“I’ve been very narrowly focused on arthroscopy—specifically soft tissue repair in the shoulder—since the beginning of my career in 1997,” Anderson shared. “My niche has been creating new medical devices, surgical procedures, and entire markets that didn’t previously exist.”

Anderson’s career began at Oratec Interventions, where he was one of the company’s earliest employees. There, he played a key role in developing and commercializing medical devices that use controlled thermal energy in the treatment of musculoskeletal soft tissue disorders, technology now used in every arthroscopic surgery worldwide. He worked closely with world-renowned sports medicine surgeons like Dr. James Andrews and Dr. Richard Hawkins (mentors to Anderson), who used the technology to save the careers of hundreds of professional athletes. He also co-designed and developed the first deflectable radiofrequency probes for hip arthroscopy with Dr. Marc Philippon, devices that Philippon used to bring countless world champions and elite-level athletes back to their original level of play after surgery, the first of his high-profile athletes being professional golfer Greg Norman back in 2000. “It seems like just yesterday that we were in that case together,” Anderson recalled. The company went public and was later acquired by Smith & Nephew for $310M after just five years and $48M in sales. 

Following that success, Anderson was involved in two early-stage sister companies that pioneered the use of proprietary web-based e-registries to aggregate and disseminate clinical outcomes data in real-time during pivotal global clinical trials, like the first drug-eluting stents, and provided FDA-mandated post-market surveillance for implantable devices in both cardiac and orthopedic surgery. Both companies were successfully sold within just a few years.

He then joined Opus Medical, where he helped develop and commercialize the first knotless tensionable suture anchor and a novel suture passer, breakthroughs that transformed rotator cuff repair by making procedures faster and more reproducible regardless of the skill level of the surgeon. “We performed the first commercial case with Dr. John Uribe, former Team Surgeon for the Miami Dolphins, in August 2003. The company was acquired by ArthroCare (now part of Smith & Nephew) in September 2004 for $130M after $17M in sales. It was an incredible ride,” stated Anderson.

Anderson continued shaping the sports medicine landscape at Tornier, where he was hired by CEO Doug Kohrs as Global Vice President - Sports Medicine, Biologics, and Commercial Development to create a top of world-class sports medicine and biologics division and product portfolio from $0 baseline, as part of a global wrap up in the extremities space. “As part of the executive team, we strategically scaled the company from $70M to $300M in five years, took the company public, and sold the company to Wright Medical in a merger valued at $3.3B (now part of Stryker). Tornier held the number three global franchise position in shoulder arthroplasty, but they had no sports medicine presence to leverage the value of the relationships they had with the world’s top shoulder surgeons,” Anderson said. “The first product I commercialized at Tornier was the world’s first knotless tensionable suture anchor made from shape memory nitinol. The second was the world’s first device ever developed for “anchorless” arthroscopic transosseous rotator cuff repair, a device and surgical technique originally developed by one of my best friends, legendary shoulder specialist Dr. Sumant “Butch” Krishnan, who I had the honor of serving as best man in his wedding. He used the device we developed and commercialized and the anchorless transosseous surgical technique he pioneered solo to repair my cuff perfectly after tearing it during jiu-jitsu. In fact, Dr. Krishnan has not used a suture anchor for rotator cuff repair in a single patient since 2005…they are just not needed.” 

Now, as Chairman, President, and CEO of Tensor Surgical, Anderson and company Co-Founder Dr. Brett Sanders, a triple fellowship and Harvard-trained shoulder surgeon, are taking on what they see as the next major shift in orthopedic surgery: eliminating the need for suture anchors in rotator cuff repair and other soft tissue repair procedures to reduce pain, eliminate suture anchor-related complications, improve outcomes, and significantly lower costs. “The shift away from anchors is not theoretical—it’s a global movement that is already happening. Dr. Sanders and I identified this critical inflection point years ago and developed strategies to commercialize innovative anchorless products and solutions that are more beneficial for patients than suture anchors and significantly more profitable for providers to use, especially in cost-constrained outpatient settings,” said Anderson. “Recruiting Justin Anderson as Tensor’s CEO is like having Elon Musk decide to run your electric car company; he literally commercialized the first mover in the space,” stated Dr. Sanders. “As a proven passionate leader with vast experience commercializing paradigm-shifting technology, Mr. Anderson brings the insight and high-level industry expertise in niche domains that will bring Tensor to the forefront of the outpatient shoulder market worldwide.”

The Current Landscape

Since the first documented rotator cuff repair 114 years ago, and still, to this day in 2025, the “gold standard” long-term clinical and structural outcomes for the repair of medium to massive-sized rotator cuff tears are “open” transosseous rotator cuff repair, which requires a 4-6cm incision to access a tear directly and repair it under direct visualization. A large needle is used to pass sutures through bone, then through the torn tissue, numerous times in a cerclage fashion, which is a load-sharing technique. “The only reason the first suture anchor was even developed back in 1985 was because we couldn’t figure out how to make intersecting transosseous tunnels and simultaneously pass sutures through bone in a minimally invasive arthroscopic fashion. Their ease of use ushered in a new era for the adoption of arthroscopic rotator cuff repair, but this came with significant added costs and tradeoffs. Despite three decades of technological evolution, the use of anchors has not improved healing rates over what can be accomplished without them, despite billions spent. They would not have been developed if we could have figured out how to perform a lower cost, minimally invasive repair that yields equivalent to better outcomes in a more reproducible fashion,” Anderson explained. 

“They have their place for sure,” Anderson added, “but their continued widespread clinical use is not taking us in the direction we need to go to improve outcomes in the post-COVID modern era of value-based care for which we are all accountable.” 

Suture anchors have become the standard fixation method for rotator cuff repair; however, the drawbacks of the “load-bearing” technique are well-documented:

• High Costs: Each anchor typically costs between $450 and $800, with most cases requiring multiple anchors, which can add up to $4,000 per procedure. This makes the total implant cost per case unsustainable in a value-based reimbursement model. Tensor Surgical saves facilities an average of $1,100 per case, allowing high-volume procedures like rotator cuff repair to be performed profitably in ambulatory surgery centers, regardless of payor mix, with no increase in operative time.
  
  
• Pain, Bone Damage, and New Modes of Anchor-Induced Failures: “The human body just does not like things inside of the bone. As it turns out, anchors violate cancellous bone and are known to create lysis around the anchors, create cystic defects inside the bone, and elevate intraosseous pressure, which is a source of deep bone pain,” Anderson explained. “Level 1 studies now prove that patients operated with an anchorless transosseous technique had significantly less pain. All of the healing comes from bone, as bone is the only vent of blood to heal torn or damaged tendons. In fact, it is now well documented in the literature that vascularity and blood flow are significantly greater through transosseous tunnels where there are no anchors than for anchor-based repairs. They violate bone and make revision surgery harder, more costly, and less successful. Type 2 failure at the myotendinous junction, which is often catastrophic and leads to more invasive surgery, is an anchor-induced phenomenon—something we have never seen with transosseous repairs.”

• Complications for Future Surgery: “The explosion in the number of reverse total shoulder replacements being performed globally each year is a huge red flag,” Anderson cautioned. “In patients with large rotator cuff tears and cuff tear arthropathy, the muscles of the rotator cuff no longer function. The great novelty of this procedure is that it relies on the deltoid muscle, instead of the rotator cuff, to power and position the arm. It essentially recreates the function of the rotator cuff, which is removed during the procedure. When performed well in the properly selected patient, the long-term success rates (10+ years) and patient-reported outcomes are high and predictable. However, we are starting to see and make correlations between earlier than normal failures (<2 years) in patients who received reverse total shoulder replacement and who also had prior ipsilateral (same-sided) shoulder surgery, specifically prior anchor-based rotator cuff repair. Prior to performing a reverse, a surgeon has to meticulously pick out all previously placed suture anchor materials and try to leave enough bone stock to implant a well-fixed prosthesis, preferably without the use of bone cement. With the most common causes of revision surgery after reverse total shoulder arthroplasty stemming from prosthetic instability, infection, and humeral problems, including loosening—especially in those whose bone is compromised from peri-anchor cysts and anchor-related complications—bone preservation strategy should be of the utmost importance to every orthopedic surgeon.”

“Healthcare Systems are recognizing the important role Tensor plays in solving this massive problem,” Anderson added. “Multi-billion-dollar healthcare systems have turned to Tensor to help them reduce the $10M+ each of them spends annually on suture anchors for rotator cuff repair alone and the high inventory carrying costs associated with multiple vendors. People have contacted us to help reduce the $1B+ these systems spend in aggregate each year managing the long-term care costs associated with suture anchor-related complications. Dr. Sanders and I take the moral and ethical responsibility of driving transformational change in healthcare very seriously. It’s been a long, hard road fighting a variety of internal and external factors as well as industry dogma to build a category-defining AI-driven medical device company that is paving the road for the future of soft tissue repair. As you can probably ascertain, companies don’t like it when domain experts with nearly three decades of experience bring to light what all major companies have been incentivized not to pay attention to. If you understand this, you understand our cause.”

Inside the Innovation

Tensor Surgical’s value-based, anchorless TransOs Tunneler soft tissue repair system is designed to improve upon the gold-standard outcomes of open transosseous repair without the need for suture anchors. By eliminating and/or significantly reducing anchors, Tensor’s system preserves native bone, enhances healing, significantly reduces pain, eliminates anchor-related complications, and dramatically lowers procedural costs without increasing surgical time.

Tensor’s solution restores this natural fixation method while offering several key advantages over traditional anchor-based repairs:

• Eliminates Anchor-Based Complications: 
• No risk of anchor pull-out, migration, or breakage
• Eliminates the risk of implant-related cysts, bone loss, and migration 
• Avoids issues with mechanical and anchor material-related complications and inflammatory responses

• Improved Biomechanics: 
  • Broad load-sharing tissue compression
  • Mimics native tendon insertion with the restoration of anatomical footprint
  • Direct tendon-to-bone contact enhances biological healing with improved vascularity

• Value-Based, Cost-Effective:
  • Reduces implant costs with the potential to eliminate anchors entirely
  • Can be used synergistically with all known fixators
  • Especially valuable in multi-tendon or large/massive tears that typically require multiple fixation points

• Load Sharing, Bone Preserving:
  • No foreign bodies left in the bone or in the healing zone
  • Useful for revision cases where previous anchors failed or bone stock is compromised or limited
  • Unlike suture anchors, which create bone voids and complicate revision surgeries, Tensor’s system leaves bone intact, reducing complications if future surgery is needed.

• Significant Reduction in Post-Operative Pain 
  • Peer-reviewed Level 1 studies report significantly lower post-operative pain scores and faster recovery compared to anchor-based repairs.
  • Higher patient satisfaction scores

• Lower Procedural Costs:
• Tensor Surgical’s TransOs Tunneler System eliminates the need for expensive anchors, reducing implant costs by an average of $1,400-$1,500 per case.

“Surgeons are under increasing pressure to reduce costs while maintaining high-quality care,” Anderson said. “With our solutions, surgeons can deliver equivalent to better outcomes at significantly reduced cost. This is the very essence of value-based care. It’s a win for all stakeholders.”

Progress and Milestones

Tensor Surgical has reached 10,000 successful procedures, proving both clinical efficacy and cost-effectiveness. The company has secured national contracts and utilization initiatives with major healthcare systems, including CommonSpirit Health.

“We are now at an inflection point,” Anderson said. “We’re profitable, we have customers driving business to us, we have operationally efficient AI-driven systems and processes in place internally, and we’re ready to scale globally.”

To support profitable expansion at scale and the commercialization of equally novel products in the company’s development pipeline, Tensor Surgical has invested in AI as a scalability unlock that traditional MedTech companies with antiquated business models lack. This includes Anderson’s programming of a state-of-the-art inventory management system with AI-driven demand forecasting and predictive insights, as well as an AI-driven digital quality management system. He is also in the process of modeling out all future product development projects with AI-generated digital twins created using NVIDIA’s Omniverse, which will speed up development time from years to months and months to minutes through the use of simulation models that can optimize product design and performance thousands of times faster than traditional engineering methods. Anderson also designed, built, and maintains a world-class ISO Class 4 Cleanroom and Sterile Packaging Laboratory in Tensor Surgical’s Las Vegas-based office, for which he was one of only five recipients in the world to receive the coveted 2024 Sterile Aware Superstars in Healthcare Packaging Innovation Award. “Our AI-driven platforms provide advantages that are not easy to replicate. Vertical integration will provide the operational leverage we need to increase our margins from ~80% to a target of 85% and achieve capital efficient growth, already evidenced by our 6.44x LTV:CAC ratio,” Anderson explained. “And unlike big medtech companies that pocket the savings, we’re passing that cost reduction directly to our customers, which will allow Tensor Surgical to grow our global addressable market size by making the highest quality care affordable for people in every country.” Anderson stated, “Behind the scenes over the last four years, we built a new breed of AI-centric medical device company with a de-risked scale-up plan. 

With a direct-to-end-user facility business model, built-in seamless adoption via national contracts, and an unprecedented National Anchorless Soft Tissue Repair customer-led Utilization Initiative recently implemented within a $33B healthcare system, Tensor Surgical is cementing its position as a disruptive force in orthopedic surgery for years to come.

Join Us at LSI Asia ‘25

Justin Anderson has been selected to present at LSI Asia '25 (June 10-13) in front of hundreds of global medical technology companies. Join us in welcoming Anderson to the event in Singapore, where he will share the latest updates on Tensor Surgical’s technology and development.